Qiagen NV (QGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qiagen NV (QGEN) has a cash flow conversion efficiency ratio of 0.030x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($100.63 Million) by net assets ($3.33 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Qiagen NV's balance sheet to measure how much of total assets are equity-financed.
Qiagen NV - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Qiagen NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check QGEN cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Qiagen NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qiagen NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Voestalpine AG
VI:VOE
|
0.042x |
|
Yes Bank Limited
NSE:YESBANK
|
0.238x |
|
UNO Minda Limited
NSE:UNOMINDA
|
0.040x |
|
99 Speed Mart Retail Holdings Berhad
KLSE:5326
|
0.085x |
|
Allegro Microsystems Inc
NASDAQ:ALGM
|
0.037x |
|
DUFRY AG UNSP.ADR/010
F:D2JA
|
N/A |
|
Sonic Healthcare Ltd
AU:SHL
|
0.078x |
|
Shenyang Fortune Precision Equipment Co. Ltd. A
SHG:688409
|
N/A |
Annual Cash Flow Conversion Efficiency for Qiagen NV (1995–2025)
The table below shows the annual cash flow conversion efficiency of Qiagen NV from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see Qiagen NV market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.78 Billion | $654.33 Million | 0.173x | -8.27% |
| 2024-12-31 | $3.57 Billion | $673.55 Million | 0.189x | +56.48% |
| 2023-12-31 | $3.81 Billion | $459.45 Million | 0.121x | -41.52% |
| 2022-12-31 | $3.47 Billion | $715.26 Million | 0.206x | -0.01% |
| 2021-12-31 | $3.10 Billion | $639.00 Million | 0.206x | +17.28% |
| 2020-12-31 | $2.80 Billion | $492.27 Million | 0.176x | +34.90% |
| 2019-12-31 | $2.54 Billion | $330.84 Million | 0.130x | -4.40% |
| 2018-12-31 | $2.63 Billion | $359.50 Million | 0.136x | +20.89% |
| 2017-12-31 | $2.54 Billion | $286.78 Million | 0.113x | -13.86% |
| 2016-12-31 | $2.61 Billion | $341.60 Million | 0.131x | +5.73% |
| 2015-12-31 | $2.56 Billion | $317.50 Million | 0.124x | +14.39% |
| 2014-12-31 | $2.66 Billion | $287.96 Million | 0.108x | +13.96% |
| 2013-12-31 | $2.72 Billion | $258.96 Million | 0.095x | +5.77% |
| 2012-12-31 | $2.72 Billion | $244.88 Million | 0.090x | -6.08% |
| 2011-12-31 | $2.56 Billion | $244.78 Million | 0.096x | -5.49% |
| 2010-12-31 | $2.48 Billion | $250.75 Million | 0.101x | +6.92% |
| 2009-12-31 | $2.29 Billion | $217.00 Million | 0.095x | -20.41% |
| 2008-12-31 | $1.45 Billion | $173.00 Million | 0.119x | +95.32% |
| 2007-12-31 | $1.39 Billion | $84.81 Million | 0.061x | -66.01% |
| 2006-12-31 | $566.16 Million | $101.48 Million | 0.179x | -11.51% |
| 2005-12-31 | $450.46 Million | $91.24 Million | 0.203x | +50.74% |
| 2004-12-31 | $400.38 Million | $53.80 Million | 0.134x | -29.78% |
| 2003-12-31 | $334.79 Million | $64.06 Million | 0.191x | +37.19% |
| 2002-12-31 | $263.03 Million | $36.69 Million | 0.139x | -48.86% |
| 2001-12-31 | $212.97 Million | $58.09 Million | 0.273x | +15.47% |
| 2000-12-31 | $164.58 Million | $38.87 Million | 0.236x | -16.39% |
| 1999-12-31 | $92.66 Million | $26.18 Million | 0.282x | +78.02% |
| 1998-12-31 | $73.10 Million | $11.60 Million | 0.159x | +0.81% |
| 1997-12-31 | $54.00 Million | $8.50 Million | 0.157x | +83.13% |
| 1996-12-31 | $47.70 Million | $4.10 Million | 0.086x | -73.11% |
| 1995-12-31 | $12.20 Million | $3.90 Million | 0.320x | -- |
About Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technol… Read more